Veradermics Doses First Patient in a First-in-Human Clinical Trial for VDPHL for the Treatment of Pattern Hair Loss (Androgenetic Alopecia)
Veradermics Doses First Patient in Phase 2 Clinical Trial for VDMN for the Treatment of Common Warts
Veradermics Inc. Secures Licensing of First-in-Class Antiviral Targeting the Treatment of Molluscum Contagiosum and other Poxviruses
Veradermics CEO Reid Waldman is selected as a Forbes 30 Under 30 for 2024
This Startup Raised $20.7 Million To Develop A Kid-Friendly Wart Treatment
Why Are We Still Killing Warts the Way We Did in the 1950s? Rethinking a pesky condition.
Kansas City dermatologist launches startup to address common childhood ailment